On Tuesday, March 9, Novartis received approval (press release, PR Newswire, Mar 2021) for Kymriah (CD19 CAR-T) in pediatric r/r ALL and adult r/r DLBCL by Singapore’s Health Sciences Authority (HSA). Of note, Kymriah is now the first commercially approved CAR-T therapy in the region. Below, Celltelligence provides insights on how Novartis could leverage Kymriah’s approval in Singapore to expand within the Asia-Pacific market, Singapore’s pivot towards cell therapy manufacturing, and how BMS and Gilead compare in the region.
About The Author
The Celltelligence Team
Content Leads & Contributors
The Celltelligence team has combined experience in oncology, including cell therapy, CAR-T, immunology, microbiology, biochemistry, and other various fields in life sciences. Our team members include PhDs, industry veterans, and analysts tuned to The Street – all of whom help to create a more actionable service of delivering cell therapy intelligence.
If you receive our email blasts, you already have an account. Log in now
Sign UpFREE
You’ll be able to access the full article from your Celltelligence Library after signing up.
If you receive our email blasts, you already have an account. Log in now
Context counts when making decisions.
Sign UpFREE
You’ll be able to access the full article from your Celltelligence Library after signing up.